Clinical trial · Observational
Prospective Prostate Cancer and Patient-reported Outcomes Registry
Promoting Quality of Care: a Prospective Cohort Study of Localized and Locally Advanced Prostate Cancer Patients
NCT04694924CI-TRIAL-00077378ProsquarerecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to evaluate the use of a digital solution, integrated into the electronic health record, for prospective and structured reporting of clinical and patient-reported outcomes for patients diagnosed with localized or locally advanced prostate cancer.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma of the Prostate | Prostate Adenocarcinoma | ALIAS | 0.90 |
| Locally Advanced Prostate Adenocarcinoma | Prostate Adenocarcinoma | CURATED_BROADER | 0.78 |
| Locally Advanced Prostate Carcinoma | Prostate Carcinoma | CURATED_BROADER | 0.78 |
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| standard of care | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Localized and locally advanced prostate cancer
- description
- Localized prostate cancer (cT1a-T2c N0 M0) refers to the clinical condition where cancer is confined to the prostate gland, in the absence of lymph node invasion or metastases. Locally advanced refers to the extension of the tumor beyond the capsule of the prostate (cT3-T4) or the clinical presence of nodal invasion (cN+), without metastases.
- interventionNames
- Other: standard of care
Primary outcomes (2)
- measure
- Assessment of systematically reporting a standardized set of predefined clinical parameters
- timeFrame
- up to 10 years after diagnosis
- description
- The proportion of patients who are enrolled in the registry over the total localized and locally advanced prostate cancer patients
- measure
- Assessment of systematically collecting a predefined set of patient-reported outcomes
- timeFrame
- up to 10 years after diagnosis
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathology confirmed diagnosis of localized or locally advanced prostate cancer * Being able to speak, read and understand Dutch, French, or English * Each patient (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he understands the purpose of, and is willing to participate in the study. Exclusion Criteria: * Patients with prior treatment for prostate malignancies will be excluded. * Dementia, mental alteration, or psychiatric pathology that can compromise informed consent from the patient and/ or adherence to the protocol and the monitoring of the trial * Patients who cannot submit themselves to following the protocol for psychological reasons, social, family, or geographical. * Persons deprived of liberty or under guardianship
References
Publications (0)
Data not yet available
No reference posted for this study.